Janssen Research & Development, LLC today announced it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for simeprevir , an investigational NS3/4A protease inhibitor, administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C ... (more)
http://www.drugs.com/nda/simeprevir_130329.html?
http://www.drugs.com/nda/simeprevir_130329.html?
No comments:
Post a Comment